Welcome to Cardiology Today – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like triglycerides and antisense oligonucleotide. Key takeaway: CRISPR-Cas9 Gene Editing for Lipids. Article Links: Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. (The New England journal of medicine) Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. (The New England journal of medicine) Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. (The New England journal of medicine) Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. (The New England journal of medicine) Article 5: Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. (The New England journal of medicine) Full episode page: https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/ Featured Articles Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211954 Summary: This meta-analysis was conducted at the individual-patient level to clarify the benefit of beta-blockers following myocardial infarction in patients with a preserved left ventricular ejection fraction of at least 50 percent. Using data from five open-label trials, the research established a robust methodology to evaluate clinical outcomes. It specifically aimed to determine the impact of beta-blocker therapy versus no therapy on a primary composite endpoint, addressing a critical area of clinical uncertainty in this patient population. This study helps establish clinical guidance for beta-blocker use after myocardial infarction in patients without significantly reduced ejection fraction. Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211945 Summary: This phase 1 ascending-dose trial was conducted to assess the safety and efficacy of CTX310, a lipid-nanoparticle-encapsulated clustered regularly interspaced short palindromic repeats-Cas9 endonuclease targeting ANGPTL3. The rationale for this gene-editing therapy is based on observed ANGPTL3 loss-of-function genetic variants, which are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides, and a reduced lifetime risk of atherosclerotic cardiovascular disease. This study represents an important first step in investigating a novel gene-editing approach to lipid management, potentially offering a transformative therapeutic strategy for cardiovascular disease prevention. The research establishes foundational data for a promising new class of treatments aimed at modifying genetic risk factors. Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211931 Summary: This international, open-label, randomized trial involving 1284 patients aimed to determine if successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy. Patients had undergone successful ablation at least 1 year earlier and had a C.H.A.2.D.S.2.-V.A.S.c score of 1 or more, or 2 or more for women. The study employed a blinded-outcome-assessment design to rigorously compare antithrombotic strategies. This research is crucial for optimizing post-ablation care and could significantly reduce treatment burden for patients with atrial fibrillation. Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211925 Summary: This international, double-blind, randomized, placebo-controlled trial investigated the effect of the proprotein convertase